Acute Myeloid Leucemia Clinical Trial
— AML F18-FLTOfficial title:
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML
| NCT number | NCT01592266 |
| Other study ID # | 0112-12-HMO |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | N/A |
| First received | April 16, 2012 |
| Last updated | May 3, 2012 |
| Start date | October 2012 |
PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a
precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution.
Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic
disease either in bone marrow or extramedullary.
F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as
well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive
study can replace bone marrow biopsy and predict response vs. non response to therapy.
| Status | Not yet recruiting |
| Enrollment | 10 |
| Est. completion date | |
| Est. primary completion date | October 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - new diagnosis of AML Exclusion Criteria: - pregnancy |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Israel | Hadassah Hebrew University Medical Center | Jerusalem |
| Lead Sponsor | Collaborator |
|---|---|
| Hadassah Medical Organization |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measure of extent and intensity ( by standardized uptake value - SUV) of disease in bone marrow demonstrated on PET/CT images before and after treatment. | |||
| Secondary | prediction of treatment response by dynamics of FLT uptake(by SUV)in comparison to bone marrow biopsy |